2.Holistic Approach to Functional Constipation: Perspective of Traditional Persian Medicine.
Majid NIMROUZI ; Mohammad M ZARSHENAS
Chinese journal of integrative medicine 2019;25(11):867-872
Traditional Persian medicine (TPM) proposes a different viewpoint to the chronic diseases. Diagnosis and implemented treatment are based on individual differences among patients. Constipation or Ea'teghal-e-batn is a condition in which the patient develops difficult or painful defecation. Based on TPM concepts, the fifirst digestion step starts from halq (oral cavity), and ends via defecation from the maq'ad (anus). Avicenna believed that four faculties, ha'zemeh (digestive), ja'zebeh (absorptive), ma'sekeh (retentive) and da'fe'eh (propulsive), are involved in the process of digestion and absorption of the ingested food and expelling the waste materials. The bowel movement and appearance of the stool is a measure for evaluating the gastrointestinal healthy function. Defecation should be with no pain and fecal material should have no burning and acuity. Low food intake or foods with dry temperament, dryness of gastrointestinal tract, diaphoresis and heavy exercise as well as intestine sensory loss were discussed as main causes of constipation. Management of constipation in TPM includes dietary schemes, oil massages and subsequently simple herbal medicines. According to TPM theories, the fifirst step in treating a disease is the elimination of disease causes (asbabe- maraz) and also providing the causes of health (asbab-e-sehhat). Health care providers should know the proper condition which the herbal medicines should be administered in and be able to guide the patients about the benefifits and hazards of herbal remedies, commonly used in their living origin.
3.Optimal fluid intake in daily diet: Avicenna's view.
Majid NIMROUZI ; Vahid TAFAZOLI ; Babak DANESHFARD ; Manijhe ZARE
Journal of Integrative Medicine 2016;14(4):241-244
Adequate daily water consumption is an important factor of keeping regular homeostasis. However, the best quantity of daily water consumption for a healthy individual is not virtually stated in the literature. Despite the dearth of evidence-based recommendations, it is commonly thought that ingesting eight glasses of water a day is good for a healthy person. Avicenna had a unique viewpoint. He believed that daily water intake depended on numerous elements together with age, intercourse, body temperament, season, occupation and various internal and external elements. He also cited a few essential and useful measures regarding proper water consumption, which have additionally been emphasized in Islamic hadiths.
6.The use of Chinese herbal drugs in Islamic medicine.
Mojtaba HEYADRI ; Mohammad Hashem HASHEMPUR ; Mohammad Hosein AYATI ; Detlev QUINTERN ; Majid NIMROUZI ; Mojtaba HEYADRI
Journal of Integrative Medicine 2015;13(6):363-367
This paper investigates some of the ways that Chinese medicine has been transferred to the Western world and to Islamic territories. During the Golden Age of Islam (8th to 13th century CE), the herbal drug trade promoted significant commercial and scientific exchange between China and the Muslim world. Chinese herbal drugs have been described by medieval Muslim medical scholars such as Tabari (870 CE), Rhazes (925 CE), Haly Abbas (982 CE), Avicenna (1037 CE) and Jurjani (1137 CE). The term al-sin (the Arabic word for China) is used 46 times in Avicenna's Canon of Medicine in reference to herbal drugs imported from China. Cinnamon (dar sini; "Chinese herb"), wild ginger (asaron), rhubarb (rivand-e sini), nutmeg (basbasa), incense tree wood (ood), cubeb (kababe) and sandalwood (sandal) were the most frequently mentioned Chinese herbs in Islamic medical books. There are also multiple similarities between the clinical uses of these herbs in both medical systems. It appears that Chinese herbal drugs were a major component of the exchange of goods and knowledge between China and the Islamic and later to the Western world amid this era.
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Islam
7.Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels: a double-blind placebo-controlled randomized clinical trial.
Zahra HAJMOHAMMADI ; Mojtaba HEYDARI ; Majid NIMROUZI ; Pouya FARIDI ; Mohammad Javad ZIBAEENEZHAD ; Gholamhossein Ranjbar OMRANI ; Mesbah SHAMS
Journal of Integrative Medicine 2018;16(1):45-50
BACKGROUNDLipid-lowering effect of Rhus coriaria L. (Rhus) has been investigated in multiple animal studies with promising results. Nonetheless, its clinical efficacy has not been adequately examined.
OBJECTIVEThe aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONSThe study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyperlipidemia were randomly assigned to receive Rhus capsules or placebo for 6 weeks.
MAIN OUTCOME MEASURESThe serum lipid levels, apolipoprotein-A1 (Apo-A1) and apolipoprotein-B (Apo-B) were measured.
RESULTSMean serum high-density lipoprotein cholesterol (HDL-C) and Apo-A1 levels were significantly increased in the Rhus group, compared with the placebo group, after 6 weeks of intervention (P = 0.001). The analysis of covariance test including age, gender, body mass index (BMI), and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipoprotein cholesterol and triglyceride levels; however, more significant improvement was observed among obese patients (BMI ≥ 30 kg/m).
CONCLUSIONThe study showed significant increases in HDL-C and Apo-A1 levels in response to Rhus supplementation in patients with hyperlipidemia.
TRIAL REGISTRATIONClinicalTrials.gov ID: NCT02295293.
8.Effects of Zataria oxymel on obesity, insulin resistance and lipid profile: A randomized, controlled, triple-blind trial.
Jafar ABOLGHASEMI ; Mohammad Ali FARBOODNIAY JAHROMI ; Mohammad HOSSEIN SHARIFI ; Zohreh MAZLOOM ; Leila HOSSEINI ; Nasrindokht ZAMANI ; Majid NIMROUZI
Journal of Integrative Medicine 2020;18(5):401-408
BACKGROUND:
Obesity is a major public health problem and its occurrence is markedly increasing in developed and developing countries. However, few studies have investigated the use of natural products to treat obesity. The effects of taking a combination of oxymel and Zataria multiflora Boiss. (ZM), herein referred to as Zataria oxymel (ZO), on obesity, lipid profile and insulin resistance have not yet been studied.
OBJECTIVE:
This study evaluates the effects of oxymel and ZO on obesity, lipid profile and insulin resistance.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS:
In this randomized, controlled, triple-blind trial, overweight patients were randomly divided into three groups and received doses of study compounds twice per day for twelve weeks. Group A received 0.75 g ZM in 10 mL oxymel in each treatment; group B received 1.5 g ZM in 10 mL of oxymel in each treatment and group C (control) only received 10 mL of oxymel in each treatment.
MAIN OUTCOME MEASURES:
Anthropometric parameters, including body mass index (BMI), waist circumference and hip circumference, were measured at the time of registration. Blood tests were carried out at the beginning and once again at end of the study. Blood parameters included fasting blood sugar (FBS), insulin levels, serum lipid profile (total cholesterol, triglyceride, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol) and liver enzymes (aspartate transaminase and alanine transaminase). Serum creatinine was also measured at the beginning of the project and in monthly intervals for three months. The homeostasis model assessment index was calculated as fasting insulin (μIU/mL) × FBS (mg/dL)/405.
RESULTS:
The results showed that patients receiving ZO experienced significant reduction in waist circumference in groups A, B and C, respectively (P < 0.001) but no significant change in BMI. Group A also experienced reduction in hip circumference (P = 0.01). Groups B and C had reduction in the homeostatic model assessment of insulin resistance (P = 0.05 and P = 0.01, respectively), with no significant reduction in FBS. No effect on lipid profile, liver enzymes or serum creatinine was observed in the three groups.
CONCLUSION:
In this study, treatment with ZO and oxymel reduced insulin resistance, and waist and hip circumferences in overweight patients. Nonetheless, the traditional Persian use of ZO as a beverage to improve the anthropometric indices in overweight individuals still requires further research with a larger sample size.
TRIAL REGISTRATION
Iranian Registry of Clinical Trials Code IRCT20171220037976N1.